Related Experiment Video
Updated: Apr 22, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
The use of biomarkers in human pharmacology (Phase I) studies
A F Cohen1, J Burggraaf, J M A van Gerven
1Centre for Human Drug Research, 2333 CL Leiden, The Netherlands;
Abstract:
The development of a new medicine is a risky and costly undertaking that requires careful planning. This planning is largely applied to the operational aspects of the development and less so to the scientific objectives and methodology. The drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot be immediately introduced in large clinical trials. The effects of the drug on normal physiology, pathophysiology, and eventually the desired clinical effects will need to be evaluated in a structured approach, based on the definition of drug development as providing answers to important questions by appropriate clinical studies. This review describes the selection process for biomarkers that are fit-for-purpose for the stage of drug development in which they are used. This structured and practical approach is widely applicable and particularly useful for the early stages of innovative drug development.
More Related Videos
Related Concept Videos
Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacogenetics of Drug Metabolism: Overview
Measurement of Bioavailability: Pharmacokinetic Methods
Bioavailability Study Design: Healthy Subjects Versus Patients

